Holen Sie sich die Stockscreener-App
13.76
0.44%
0.06
Vorhandelsmarkt:
13.39
-0.37
-2.69%
Schlusskurs vom Vortag:
$13.70
Offen:
$13.61
24-Stunden-Volumen:
4.08M
Relative Volume:
1.48
Marktkapitalisierung:
$1.19B
Einnahmen:
$139.71M
Nettoeinkommen (Verlust:
$-209.36M
KGV:
-4.6486
EPS:
-2.96
Netto-Cashflow:
$-160.60M
1W Leistung:
+4.96%
1M Leistung:
-11.79%
6M Leistung:
+0.22%
1J Leistung:
-27.50%
1-Tages-Spanne:
$13.36
$14.36
1-Wochen-Bereich:
$13.02
$14.36
52-Wochen-Spanne:
$8.58
$22.50
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
730 THIRD AVENUE, NEW YORK, MA
Vergleichen Sie SNDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
13.76 | 1.18B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-09-10 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax: Q3 Earnings Snapshot - CT Insider
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Insight - GuruFocus
Syndax Pharmaceuticals Reports Strong Q3 2025 Growth - TipRanks
Syndax Pharmaceuticals (SNDX) Q3 2025 Earnings: Revenue Jumps 21% - GuruFocus
Syndax targets $10B market as Revuforj gains NPM1 approval and Q3 revenue rises 21% - MSN
Will Syndax Pharmaceuticals Inc. stock maintain momentum in 2025July 2025 Setups & Safe Swing Trade Setup Alerts - newser.com
Syndax Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Transcript : Syndax Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Is Syndax Pharmaceuticals Inc. stock reversal real or fakeGap Down & Weekly High Potential Alerts - newser.com
Syndax Pharmaceuticals Q3 Earnings: EPS of -$0.70 Beats Estimate, Revenue of $45.9M Misses Estimate - GuruFocus
Syndax Pharmaceuticals Grows Revenue As Wall Street Stays Bullish - Finimize
Earnings Flash (SNDX) Syndax Pharmaceuticals, Inc. Reports Q3 Revenue $45.9M, vs. FactSet Est of $48.0M - MarketScreener
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Syndax Pharmaceuticals falls as Q3 revenue misses estimates - Investing.com
[10-Q] Syndax Pharmaceuticals Inc Quarterly Earnings Report | SNDX SEC FilingForm 10-Q - Stock Titan
[8-K] Syndax Pharmaceuticals Inc Reports Material Event | SNDX SEC FilingForm 8-K - Stock Titan
SNDX: Syndax Pharmaceuticals to Showcase Promising Data at ASH 2 - GuruFocus
Is Syndax Pharmaceuticals Inc. stock poised for growth2025 Technical Overview & Low Volatility Stock Recommendations - newser.com
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025 - The Manila Times
Syndax Announces Compelling Revuforj® (revumenib) and - GlobeNewswire
Syndax (NASDAQ: SNDX) to present Revuforj and Niktimvo data in 23 ASH 2025 abstracts - Stock Titan
How Syndax Pharmaceuticals Inc. stock performs in rate cut cycles2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Using Ichimoku Cloud for Syndax Pharmaceuticals Inc. technicals2025 Big Picture & Entry and Exit Point Strategies - newser.com
Leading vs lagging indicators on Syndax Pharmaceuticals Inc. performanceJuly 2025 Short Interest & Entry Point Confirmation Alerts - newser.com
Is Syndax Pharmaceuticals Inc. (1T3) stock undervalued by metricsMarket Activity Recap & Weekly Momentum Picks - newser.com
AlphaQuest LLC Sells 18,370 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Applying Wyckoff theory to Syndax Pharmaceuticals Inc. stockBreakout Watch & Verified Technical Trade Signals - newser.com
Detecting support and resistance levels for Syndax Pharmaceuticals Inc.Jobs Report & Verified Swing Trading Watchlist - newser.com
Is it too late to sell Syndax Pharmaceuticals Inc.Weekly Trade Summary & Growth-Oriented Investment Plans - newser.com
How Syndax Pharmaceuticals Inc. stock performs in stagflationJuly 2025 Chart Watch & Verified Momentum Watchlists - newser.com
Syndax Pharmaceuticals Q3 2025 Earnings Preview - MSN
Is Syndax Pharmaceuticals Inc. showing signs of accumulationMarket Volume Summary & AI Driven Stock Movement Reports - newser.com
Syndax Pharmaceuticals (SNDX) Q3 Earnings Preview: Key Expectati - GuruFocus
Kura Oncology's Ziftomenib Poised For Differentiation (NASDAQ:KURA) - Seeking Alpha
How risky is Syndax Pharmaceuticals Inc. stock nowJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
Y Intercept Hong Kong Ltd Makes New Investment in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
B. Riley Issues Optimistic Estimate for SNDX Earnings - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Report Previe - GuruFocus
Syndax Pharmaceuticals Hits Day Low at $13.03 Amid Price Pressure - Markets Mojo
Syndax Pharmaceuticals’ Promising AML Study Update: Key Insights for Investors - TipRanks
Is Syndax Pharmaceuticals Inc. (1T3) stock considered safe havenJuly 2025 Sentiment & Fast Moving Stock Watchlists - newser.com
Why Syndax Pharmaceuticals Inc. stock is rated strong buyJuly 2025 Selloffs & Weekly Momentum Picks - newser.com
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):